Literature DB >> 27759500

A recent trend of drug-nanoparticles in suspension for the application in drug delivery.

Gurpreet S Suri1, Amritvir Kaur1, Tapas Sen1.   

Abstract

Persistent development in nanomedicine has enabled successful nanosizing of most drug samples which, in turn, imparts remarkable properties to the drugs such as enhanced solubility and bioavailability for the applications in drug delivery. In this context, several review articles are available in scientific domain covering inorganic nanoparticles such as Au, Ag, SPIONs, Qdots, carbon nanotubes and graphene; however, this review covers the development of drug nanoparticles together with their possibilities and limitation from fabrication (bottom up vs top down) to application in drug delivery during the last 5 years. In addition, some distinguished studies and novel drug particles are presented in order to contribute significantly toward the understanding of drug nanocrystals and its use in drug delivery.

Entities:  

Keywords:  amorphous/crystalline nanoparticles; drug delivery; drug-nanocrystals; nanocarriers; nanosuspension; top down/bottom up

Year:  2016        PMID: 27759500     DOI: 10.2217/nnm-2016-0238

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  3 in total

1.  Temperature-Induced Surface Effects on Drug Nanosuspensions.

Authors:  Simone Aleandri; Monica Schönenberger; Andres Niederquell; Martin Kuentz
Journal:  Pharm Res       Date:  2018-02-21       Impact factor: 4.200

Review 2.  Coating Matters: Review on Colloidal Stability of Nanoparticles with Biocompatible Coatings in Biological Media, Living Cells and Organisms.

Authors:  Jonas Schubert; Munish Chanana
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

Review 3.  Recent progress in drug delivery.

Authors:  Chong Li; Jiancheng Wang; Yiguang Wang; Huile Gao; Gang Wei; Yongzhuo Huang; Haijun Yu; Yong Gan; Yongjun Wang; Lin Mei; Huabing Chen; Haiyan Hu; Zhiping Zhang; Yiguang Jin
Journal:  Acta Pharm Sin B       Date:  2019-08-19       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.